<DOC>
	<DOC>NCT01806415</DOC>
	<brief_summary>This is a randomized, blinded, parallel group, placebo-controlled trial on 32 evaluable healthy male and non-pregnant female, 18-50 year old volunteers. The investigators goal is to observe the pharmacokinetics of fenobam after oral administration of 50, 100 or 150 mg in groups of healthy individuals and to compare the side effects and tolerability of a single dose of fenobam with placebo.</brief_summary>
	<brief_title>Pharmacokinetics and Side Effects of the mGlu5 Antagonist Fenobam in Adult Healthy Volunteers</brief_title>
	<detailed_description>Treatment regimen 1: Fenobam [1-(3-chlorophenyl)-3-(1-methyl-4-oxo-2-imidazolidinylidine) urea hydrate], oral administration of one 50 mg gelatin capsule. Treatment regimen 2: Fenobam, oral administration of one 100 mg gelatin capsule. Treatment regimen 3: Fenobam, oral administration of one 150 mg gelatin capsule. Treatment regimen 4: Placebo (lactose), oral administration of one 150 mg gelatin capsule.</detailed_description>
	<criteria>Inclusion Criteria 1. 1850 yr old 2. Good general health with no remarkable medical conditions (e.g liver, kidney, heart, or lung failure), BMI&lt;33 and no known drug allergies. 3. Willing to comply with study guidelines as outlined in protocol 4. Willing to provide informed consent. Exclusion Criteria 1. Medication use (prescription or non prescription medications, vitamins, herbals, dietary and mineral supplements and grapefruit products during or within 14 days prior to study participation; excludes contraceptives) 2. History of addiction to drugs or alcohol (prior or present addiction or treatment for addiction) 3. Pregnant or nursing female 4. Lactose intolerance 5. Smokers</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Fenobam,</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>side effects</keyword>
</DOC>